
Pricey TikTok skin care routines for kids raise alarms in new study
Children as young as seven are making TikTok videos about their meticulous and pricey skin care routines. Known as 'Sephora Kids,' they are the focus of a new study that raises alarms about the trend.
'We found that the skin care routines posted by creators aged 18 and under were complicated, costly, and time consuming,' lead author and dermatologist Dr. Molly Hales told CTVNews.ca. 'The skin care routines offered few benefits to the young people that they were targeting, and they carried risks of irritation, skin allergy, and sun sensitivity.'
Hales is a postdoctoral research fellow at Northwestern University's medical school in Chicago. For the study, Hales and another researcher created new TikTok accounts posing as 13-year-olds. They analyzed 100 skin care videos by content creators ages 7 to 18, and recorded the number and types of products that were used, as well as the total cost of each skin care regimen.
On average, the content creators used six products per video. The average cost of the products used in each regimen was US$168 while the most expensive exceeded $500. The videos the researchers analyzed had an average of 1.1 million views.
The 25 most-viewed videos featured products with an average of 11, and a maximum of 21, ingredients that could potentially lead to skin irritation, sun sensitivity or skin allergy.
'We found significant dermatologic risks associated with these regimens, including a very high risk of irritation,' Hales added in a news release from Northwestern University. 'That high risk of irritation came from both using multiple active ingredients at the same time, such as hydroxy acids, as well as applying the same active ingredient unknowingly over and over again when that active ingredient was found in three, four, five different products.'
Only a quarter (26.2 per cent) of daytime skin regimens included sunscreen, which Hales says is an incredibly important product for young and old skin alike.
'It's really the only product that is recommended in this age group for those who don't have a known skin condition such as acne or eczema,' Hales told CTVNews.ca. 'It's particularly important given that we found in our study that the most popular active ingredients in these youth skin care routines are alpha hydroxy acids, which are known to increase sun sensitivity.'
In one video, a content creator applied 10 products to her face in six minutes – and quickly regretted it.
'You can see that she's turning bright red,' Hales said. 'She wraps up the video by saying, 'If anyone knows how to get it to stop burning, that would be greatly appreciated because it actually hurts a lot.''
Senior author and pharmacist Dr. Tara Lagu also noted potential harms that went beyond just product ingredients.
'We saw that there was preferential, encoded racial language in some cases that really emphasized lighter, brighter skin,'Lagu, an adjunct lecturer at Northwestern University, said in the news release. 'I think there also were real associations between use of these regimens and consumerism.'
Lagu got the idea for the study after asking her 12-year-old niece what she wanted for Christmas and getting a list of $300 worth of skin care products.
'After digging around a bit, she realized that nobody had done a formal study of the skin care routines that were circulating among teens and pre-teens on social media,' Hales told CTVNews.ca. 'She approached me about a potential collaboration, knowing that I'm both a dermatologist and a medical anthropologist with a background in digital and social media.'
Published in the American Academy of Pediatrics, it is the first peer-reviewed study of its kind. The study's authors conclude that the videos offer little to no benefit for their young audience. They also note that it can hard for parents to track what their children are viewing on TikTok because of age-based algorithms.
'I would encourage parents to make sure that their kids understand that they don't need to be using tons of costly products in order to have healthy skin, or to take care of themselves and their skin,'Hales told CTVNews.ca. 'These skin care videos can be fun and playful, and given their popularity, they likely aren't going away anytime soon. But it's troubling when this content sets an unrealistic standard of beauty and then promotes it in the name of 'health.''
Dr. Elena Hope, the head of pediatric dermatology at SickKids hospital in Toronto, was not involved in the study but echoed its recommendations. She said children should avoid using products with fragrances, essential oils and retinoids, urging parents to educate themselves about potentially harmful ingredients.
'Daily moisturizers that have been tested for tolerability and sunscreens are the only recommendations we have for children,' Hope said in an email to CTVNews.ca. 'All other preparations are not needed and may be harmful.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

National Post
an hour ago
- National Post
Breast Cancer Canada launches MEGABike Campaign
Article content Up to 30 riders hit the road to fuel life-saving research Article content TORONTO — Breast Cancer Canada is proud to launch their national MEGABike campaign rolling into cities across the country in a high-impact fundraiser that drives critical research forward. Article content Article content Starting July 17 in London, Ontario and culminating September 29 in Victoria, British Columbia, MEGABike 2025 invites teams of up to 29 riders to power a 30-seat bike through city streets, raising funds and awareness for the most commonly diagnosed cancer in the world: breast cancer. Article content 'MEGABike is a symbol of what we can accomplish when we move forward together,' says Kimberly Carson, CEO of Breast Cancer Canada. 'Every dollar raised supports Canadian research that improves outcomes for Canadians facing breast cancer, bringing us closer to a future where every patient receives the individualized care they need, regardless of where they live in the country.' Article content The MEGABike tour spans seven provinces, with events scheduled in more than 25 cities across Canada, including major stops such as Edmonton, Calgary, Halifax, Toronto, Montreal, St. John's, and Vancouver. Teams can register at one of two partnership levels: Article content Participants can ride with friends, colleagues, staff, or other community members in support of breast cancer research. Individuals without a full team are encouraged to join the waitlist to be matched with others in their city. Article content All funds raised support Breast Cancer Canada's mission to advance precision oncology research, helping to match the right treatment to the right patient at the right time. Article content Event Schedule: Article content Thursday, July 17 – London, Ontario Friday, July 18 – London, Ontario Saturday, July 19 – Niagara Falls, Ontario Sunday, July 20 – St. Catharines, Ontario Tuesday, July 22 – Burlington, Ontario Wednesday, July 23 – Kitchener/Waterloo, Ontario Friday, July 25 – Toronto, Ontario Saturday, July 26 – Toronto, Ontario Tuesday, July 29 – Mississauga, Ontario Wednesday, July 30 – Brampton, Ontario Thursday, July 31 – Vaughan, Ontario Thursday, August 7 – Newmarket, Ontario Friday, August 8 – Barrie, Ontario Saturday, August 9 – Orillia, Ontario Tuesday, August 12 – Sudbury, Ontario Thursday, August 21 – Moncton, New Brunswick Friday, August 22 – Saint John, New Brunswick Saturday, August 23 – Fredericton, New Brunswick Sunday, August 24 – Halifax, Nova Scotia Tuesday, August 26 – Edmonton, Alberta Wednesday, August 27 – St. John's, Newfoundland Thursday, August 28 – St. John's, Newfoundland Thursday, August 28 – Calgary, Alberta Saturday, August 30 – Lethbridge, Alberta Friday, September 12 – Montreal, Quebec Saturday, September 13 – Montreal, Quebec Monday, September 15 – Quebec City, Quebec Wednesday, September 24 – Kamloops, British Columbia Friday, September 26 – Vancouver, British Columbia Saturday, September 27 – Vancouver, British Columbia Monday, September 29 – Victoria, British Columbia Article content Breast cancer is the most diagnosed cancer worldwide Article content , with over 50 different types of breast cancer, and over Article content . MEGABike offers an energetic way for workplaces, families, and community groups to get involved in driving the progress that saves lives. Article content Register your team or learn more at: Article content Article content Article content Article content Article content Article content Contacts Article content

National Post
2 hours ago
- National Post
ImmunoPrecise Advances Universal Dengue Vaccine, Confirming Safety, Immune Activation, and Structural Stability Using its LENSai™ Platform Powered by Patented HYFT® Technology
Article content Follow-Up to June 5, 2025, Announcement Demonstrates Validated Vaccine Candidate with Strong Translational Potential Article content AUSTIN, Texas — ImmunoPrecise (NASDAQ: IPA), a leader in AI-driven biotherapeutics, provides a significant update following its June 5, 2025, press release ImmunoPrecise Announces AI-Driven Breakthrough in Universal Dengue Vaccine Discovery. This new release details the downstream validation of the epitope identified in that initial announcement—demonstrating that the computationally selected vaccine target is not only highly conserved across all four dengue virus types but also safe, immunologically active, and structurally stable. Article content Article content 'This is a major step forward,' said Dr. Jennifer Bath, CEO of ImmunoPrecise. 'Our AI technology not only found a new target for a universal dengue vaccine, but we've now shown it's safe and can trigger the right immune response. With this validation, we're excited to move ahead and advance this candidate toward the next stages of vaccine development.' Article content Following the recent discovery of a unique 'Achilles' heel' shared by all four types of dengue virus, ImmunoPrecise has confirmed—using its patented HYFT technology and LENS ai Immunogenicity Screener—that the selected target not only remains conserved but also triggers a strong and specific immune response. This breakthrough may pave the way for a safer, more universal dengue vaccine. Article content The new target was discovered using the Company's proprietary LENS ai platform. 'Our ability to move from computational discovery to AI-guided immunogenicity validation is unique to our methodology and drug development,' commented Dr. Jennifer Bath, ImmunoPrecise CEO. 'Further, it ensures that our candidates are both theoretically promising and primed for real-world immune protection, a critical requirement for any viable vaccine candidate.' Article content For decades, dengue has been one of the most challenging viruses for vaccine developers, largely because the virus comes in four different forms—and beating one doesn't guarantee protection from the others. Many vaccines fail because they trigger the immune system to attack the wrong parts of the virus, or worse, make infections more severe. What makes this development so important is that ImmunoPrecise's target has now been shown—based on in silico immune profiling—to likely engage key components of the immune system, including both B cells and T cells, in a manner that appears safe and highly specific. ImmunoPrecise's latest AI-driven testing shows that their selected target—a small, stable piece of the virus—can activate the body's defenses in a very precise way, without the risks of traditional, broader approaches. Article content A Methodology That Changes the Game—Far Beyond Dengue Article content What sets ImmunoPrecise apart is not only the discovery of a promising dengue vaccine target, but the methodology itself. With LENS ai powered by HYFT technology, IPA brings unprecedented clarity to the earliest stages of discovery—well before traditional disease modeling or animal studies even begin. By revealing deep relationships between sequence, structure, and function at the outset, this platform provides rapid, explainable insights that inform every downstream decision, from epitope selection to vaccine design. Article content The findings for dengue showcase the platform's versatility. Because HYFT technology systematically maps biological meaning across the entire biosphere, this methodology is readily transferable—equipping IPA to tackle a wide spectrum of infectious diseases, from HIV and influenza to emerging pathogens and oncology targets. With this approach, ImmunoPrecise isn't just keeping pace with the field; it's setting a new standard for how next-generation therapeutics are discovered and validated. Article content ImmunoPrecise's patented HYFT technology successfully identified a critical and discontiguous target site (epitope) that remains unchanged across all four types of dengue virus (DENV-1 through DENV-4). This target site is essential for how the virus infects cells and is believed to be key for establishing an enduring and efficacious universal dengue vaccine. Article content This HYFT-guided workflow achieves this by analyzing protein building blocks that may be far apart in the virus's genetic sequence but come together when the protein folds into its final 3D shape. This advanced mapping process combines genetic similarity analysis with 3D structural modeling and functional annotation to identify the most promising vaccine targets. Article content Complete Immune Response Testing Computer-based immune response screening used advanced prediction tools to evaluate how both antibody-producing cells (B cells) and infection-fighting cells (T cells) would respond to the vaccine target. The target site showed strong predicted binding to multiple human immune system markers (HLA class I and II types). This suggests that people from diverse backgrounds and genetic makeups could mount a strong immune response to the vaccine—something essential for global deployment. Article content Safety Verification Against Human Proteins Using ImmunoPrecise's proprietary retrieve-and-relate technology at the core of HYFT™ ( Van Hyfte et al., 2023, bioRxiv), the vaccine target was thoroughly compared against all known human and mouse proteins. This comprehensive safety check goes beyond standard comparison methods—HYFT systematically searches for not only genetic similarities but also structural and functional matches across species, ensuring the vaccine target is unique to the virus and not found in human biology. This is critical in vaccine development, where off-target effects can lead to dangerous autoimmune reactions. No problematic similarities were found, significantly reducing the risk that the vaccine would accidentally attack the body's own healthy cells. Article content Structural Stability Analysis Advanced computer modeling and molecular simulation studies have confirmed that the vaccine target maintains its proper shape, remains accessible to immune cells, and remains prominently displayed on the surface of the dengue virus. Stability testing demonstrated that the target remains robust under normal physiological conditions. Article content Balanced Immune Response Profile Importantly, the moderate predicted immune response strength (compared to typical vaccine 'hotspots') may explain why this target was overlooked in previous laboratory studies that focused on more obvious, highly immunogenic sites. This balanced profile suggests the vaccine could trigger a highly specific immune response while potentially reducing the risk of dangerous immune overreactions or antibody-dependent enhancement (ADE)—a serious complication that can worsen dengue infection. Article content Looking Ahead Article content This release is the second in a series of disclosures aimed at showcasing the power of ImmunoPrecise's end-to-end AI-native platform. The June 5th announcement introduced a promising target; today's release provides the crucial next step: a rigorous validation of that target's safety and immunological relevance. This validation significantly strengthens the translational potential of the candidate, which is currently being prepared for further preclinical evaluation. Article content These findings come at an important time, as global agencies continue to seek safer and more effective dengue vaccines. IPA is actively engaging with key stakeholders to explore the path forward, including potential collaboration, development, and funding partnerships. Article content About ImmunoPrecise Antibodies Ltd. Article content ImmunoPrecise (NASDAQ: IPA) is a global leader in AI-powered biotherapeutic discovery and development. Its proprietary HYFT technology and LENSai™ platform enable first-principles-based drug design, delivering validated therapeutic candidates across modalities and therapeutic areas. IPA partners with 19 of the top 20 pharmaceutical companies and is advancing next-generation biologics through data-driven, human-relevant models. Article content Forward-Looking Statements Article content This press release contains forward-looking statements within the meaning of applicable United States and Canadian securities laws. Forward-looking statements are often identified by words such as 'expects,' 'intends,' 'plans,' 'anticipates,' 'believes,' or similar expressions, or by statements that certain actions, events, or results 'may,' 'will,' 'could,' or 'might' occur or be achieved. These statements include, but are not limited to, statements regarding the anticipated benefits, scalability, and broader application of the LENSai™ and HYFT® platforms to dengue vaccine development; the advancement, regulatory acceptance, and future clinical potential of AI-native approaches for dengue and other infectious diseases; and the Company's ability to achieve and maintain scientific, regulatory, and commercial progress in its dengue program. Article content Forward-looking statements are based on management's current expectations, assumptions, and projections about future events. Actual results may differ materially from those expressed or implied due to a variety of factors, many of which are beyond the Company's control. These factors include, but are not limited to, the pace of scientific and technological developments, changes in regulatory requirements or acceptance of AI Article content designed vaccines, competition and market dynamics, intellectual property protection, risks related to preclinical or clinical validation of dengue vaccine candidates, integration and operational challenges, and changes in global economic or business conditions. Article content Forward-looking statements involve known and unknown risks, uncertainties, and other factors that could cause actual results, performance, or achievements to differ materially from those expressed or implied herein. Additional information regarding risks and uncertainties is included in the Company's Annual Report on Form 20-F, as amended, for the year ended April 30, 2024 (available on the Company's SEDAR+ profile at Article content Article content ). Should any of these risks materialize, actual results could vary significantly from those currently anticipated. Article content Article content Article content Article content Article content Article content


Globe and Mail
2 hours ago
- Globe and Mail
Why Did Hims and Hers Stock Crash on Monday?
In this video, I will explain why Hims & Hers Health (NYSE: HIMS) crashed over 30% on Monday. Watch the short video to learn more, consider subscribing, and click the special offer link below. *Stock prices us ed were from the trading day of June 23, 2025. The video was published on June 23, 2025. Should you invest $1,000 in Hims & Hers Health right now? Before you buy stock in Hims & Hers Health, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Hims & Hers Health wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $664,089!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $881,731!* Now, it's worth noting Stock Advisor 's total average return is994% — a market-crushing outperformance compared to172%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. *Stock Advisor returns as of June 23, 2025 Neil Rozenbaum has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Hims & Hers Health. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. Neil is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through his link, he will earn some extra money that supports his channel. His opinions remain his own and are unaffected by The Motley Fool.